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Significance Statement. 
Most of the applications involving oligonucleotide probes are based on hybridization 
with complementary targets to form a duplex. When the target sequence is a 
polypurine-polypyrimidine track it is possible to use special triplex forming 
oligonucleotides (TFO). Parallel clamps and polypurine reversed hairpins (PPRH) are 
special cases of TFOs in which the polypurine Watson-Crick strand is linked to either 
a polypyrimidine Hoogsteen strand or a polypurine reversed Hoogsteen strand. The 
high stability of the triplex formed upon binding of these TFOs with the 
polypyrimidine target allows targeting of single and double stranded nucleic acid 
sequences as these TFOs induce strand displacement. This targeting technology 
covers from gene silencing of genomic DNA and mRNA to detection of nucleic acids 
of biological interest. 
ABSTRACT 
Nucleic acid triplexes are formed when a DNA or RNA oligonucleotide binds to a 
polypurine-polypyrimidine rich sequence. Triplexes have wide therapeutic 
applications such as gene silencing or site-specific mutagenesis. In addition, 
protocols based on triplex-affinity capture have been used for detecting nucleic 
acids in biosensing platforms. In this unit we describe the design, synthesis and use 
of parallel clamps and polypurine reversed hairpins (PPRH) to bind to target 
polypyrimidine targets. The combination of the polypurine Watson-Crick strand with 
the triplex forming strand in a single molecule produces highly stable triplexes 
allowing targeting of single and double stranded nucleic acid sequences. On the 
other hand, PPRHs are easily prepared and work at nanomolar range, like siRNAs, 
and at a lower concentration than that needed for antisense ODNs or TFOs. 
However, the stability of PPRHs is higher than that of siRNAs. In addition, PPRHs 
circumvents off-target effects and are non-immunogenic. 




INTRODUCTION. Triplex forming oligonucleotides are important tools in gene 
silencing and gene analysis. The most studied triplex is the so-called parallel triplex, 
where a polypyrimidine strand binds a polypurine-polypyrimidine duplex sequence 
by formation of C+: G.C and T:A.C triads. The stability of this triplex depends on 
the pH as cytosine needs to be protonated to form the C+: G.C triad. 8-
Aminoadenine and 8-aminoguanine stabilize the parallel triplex by a combined 
effect of the gain in one Hoogsteen purine-pyrimidine H-bond and the ability of the 
amino group to be integrated into the "spine of hydration" located in the minor-
Major groove of the triplex structure (Aviñó, 2002). In order to use the beneficial 
triplex stabilization properties of 8-aminopurine, capture probes were designed as 
parallel clamps to bind to single-stranded polypyrimidine sequences. These clamps 
consisted in a purine strand carrying 8-aminopurines and the parallel stranded 
polypyrimidine sequence. Examples of the use of these clamps are the isolation of 
polypyrimidine RNA sequences of biological interest such as bacterial RNA 
(Carrascosa, 2012) and miRNA (Aviñó, 2016). The PolyPurine Reverse Hoogsteen 
(PPRH) technology is often used for targeting single and double stranded nucleic 
acid sequences (Villalobos, 2015). Several examples of PPRHs for the inhibition of 
gene expression have been described (Solé, 2017; Ciudad, 2017; Coma, 2005) as 
well as for capture of miRNA (Ribas 2018) and double-stranded DNA for the 
analysis of DNA methylation status (Huertas, 2018). 
This unit describes the design, synthesis and use of parallel clamps and polypurine 
(PPRH) hairpins for gene silencing and triplex-affinity capture.  
Basic protocol 1 describes the search of polypyrimidine-polypurine tracks and 
design of the appropriate clamps and hairpins (Figure 1). Basic protocol 2 describes 
the protocols for the synthesis of 8-amino-2’-deoxyadenine phosphoramidite. Basic 
protocol 3 describes the protocols for the synthesis of 8-amino-2’-deoxyguanosine 
phosphoramidite. Basic protocol 4 describes the synthesis of oligonucleotide clamps 
and polypurine hairpins. Basic protocol 5 describes the use of polypurine hairpins 
for gene silencing. Basic protocol 6 describes the functionalization of gold surfaces 




Figure 1. Steps in the design of parallel clamps or the PPRH. First select the 
polypyrimidine track from sequence database. Then select if parallel clamps or the 
PPRH will be used and the linking strategy (tetra- or penta-thymidine loop or 
hexaethyleneglycol) and the ends that will be connected (A, B , C, or D). P1, P2,…Pn 
purine sequence; Y1, Y2,…Yn pyrimidine sequence. 
 
BASIC PROTOCOL 1 
DESIGN OF POLYPURINE REVERSE HOOGSTEEN HAIRPINS 
The protocol describes the design of PPRHs which are formed by two mirror-repeat 
sequences of polypurines linked by a pentathymidine bridge (Figure 1). This 
involves the search of polypurine stretches within a given gene and their 
localization in the chromosome and in its specific parts such as promoter, exonic or 
intronic sequences. Thus, the complementary sequence of each one of these 
 
 
regions constitutes the polypyrimidine track which will be the target of the selected 
PPRHs. Then, the selection of sequences to build the PPRHs, among all the possible 
match found in the search, is made considering the length of the sequence, the 
number of pyrimidine interruptions and the specificity of that sequence within the 
genome of interest. Once a polypurine sequence is selected, the mirror repeat is 
determined by searching for its reverse sequence. Then, the final PPRH sequence is 
assembled by connecting these two sequences using a pentathymidine (T5) spacer, 





Triplex-Forming Oligonucleotide Target Sequence Search software: available at 
http://utw10685.utweb.utexas.edu/tfo// 
Triplex target site Mapping and Integration software: available at http://ttsmi.bii.a-
star.edu.sg) 
Reverse Complement software: available at 
https://www.bioinformatics.org/sms/rev_comp.html) 
BLASTn software: available at 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) 
 
Design of PPRHs 
1. Connect via web with http://utw10685.utweb.utexas.edu/tfo/ to look for 
Polypurine sequences using the TFO-searching Target Sequence Search. 
2. Select the species and gene. By default, Species is set at Homo sapiens, but 
it can also be changed to Mus musculus. When searching for Polypurines in 
other species, the DNA sequence and the gene of interest has to be provided 
as a .txt file in FASTA format. 
3. Enter the Gene name, either as a symbol or as Entrez Gene ID. 
4. Set the parameters, which by default are i) a minimum of 15 nt length; ii) a 
minimum of %G: 50; iii) a maximum allowable of 3 Pyrimidine interruptions; 
and iv) taking 2000 bases for the putative promoter region length. These 
parameters can be changed according to your needs or results after a first 
iteration. 
5. Select the gene in case you are offered with a variety of genes with similar 
names or with different transcripts and search for TFO target sequences. 
6. A list of polypurine sequences will appear in decreasing order of nucleotide 
length. For each sequence, the following information is given: i) the length of 
the sequence including the number and position of polypyrimidine 
interruptions (in red) up to 3; ii) the % of G ; iii) the strand of the double 
strand DNA where the polypyrimidine track is found (either forward or 
 
 
reverse) according to the chromosome orientation; iv) the position in the 
chromosome and in the gene; and the region of the gene where it is found 
(promoter, intron or exon).  
7. To analyze the specificity of each sequence it is given the possibility to 
perform automatically a BLAST (Basic Local Alignment Sequence Tool) 
analysis from NCBI to determine the similarity of the selected sequence 
within the genome of interest.  
8. BLAST analysis can also be performed manually using a chosen sequence 
from the TFO report or a selected fragment of a sequence. The query (input) 
sequence is compared with a database (e.g. nr: non-redundant) for the 
species of interest (e.g. human). 
9. The BLAST report consists of list of genes in a decreasing order of similarity 
to the input sequence quantified by a score followed by a selection of the 
sequences producing significant alignments. 
10. A Polypurine sequence is considered to be specific when the report of 
the BLAST finds out the gene of interest as the most similar among all the 
hits and with a significant distance in score with the next gene sequence. 
This distance in score in significance depends of the length of the sequence. 
For instance, for a sequence of 26 nt the difference can be around 15% less, 
corresponding to 4-5 mismatches or lack of identity. 
11. To design a particular PPRH out of a selected TFO target, paste that 
sequence into the Reverse-Complement software and determine the Reverse 
sequence. This sequence will correspond to the mirror repeat of the original 
sequence. 
12. Proceed to the design of the sequence of the PPRH in the following 
manner: Place the Polypurine sequence followed by 5 Ts which is then linked 
to the reverse sequence. The T5 will act as a loop between the two mirror 
sequences that form the hairpin bound by intramolecular reverser Hoogsteen 
bonds. 
13. If the chosen polypurine sequence is in the forward strand of the 
chromosome and the gene has forward orientation, then the designed PPRH 
is termed Template-PPRH because it would be directed against the 
polypyrimidine track in the template strand of the gene (Figure 2A). 
14. If the chosen polypurine sequence is in the reverse strand of the 
chromosome and the gene has forward orientation, then the designed PPRH 
is termed Coding-PPRH because it would be directed against the 
polypyrimidine track in the coding strand of the gene, which will also 
correspond to the sequence and orientation of the transcribed RNA (Figure 
2B). 
15. If the chosen polypurine sequence is in the forward strand of the 
chromosome and the gene has reverse orientation, then the designed PPRH 
 
 
is termed Coding-PPRH because it would be directed against the 
polypyrimidine track in the coding strand of the gene, which will also 
correspond to the sequence and orientation of the transcribed RNA (Figure 
2C). 
16. If the chosen polypurine sequence is in the reverse strand of the 
chromosome and the gene has reverse orientation, then the designed PPRH 
is termed Template-PPRH because it would be directed against the 
polypyrimidine track in the template strand of the gene (Figure 2D). 
17. It is advisable to design several PPRHs directed against each gene, for 
instance in the promoter region, and in intron and exon sequences. Also, if 
possible, design template- and coding- versions of PPRHs if the target 
sequences exist. This will allow having a broader spectrum of PPRH 
sequences for screening of their potential gene silencing effect. Regularly, it 
is enough to test 3 PPRHs to get silencing effects. 
 
Figure 2. Different permutations and nomenclature (template or coding) of 
PPRHs depending on the orientation of the gene in the chromosome (forward or 
reverse) and in which strand the polypurine stretch is found. A) Forward gene 
and Polypurine (Ppu) sequence in the forward strand, thus the Polypyrimidine 
sequence (Ppy) is in the template strand and therefore the hairpin is termed 
template-PPRH; B) Forward gene and Ppu sequence in the reverse strand, thus 
the hairpin is binding to the coding strand and named coding-PPRH; C) Reverse 
gene and Ppu sequence in the forward strand, thus the PPRH binds to the coding 
strand; and D) Reverse gene and Ppu sequence in the reverse strand, thus the 
PPRH binds to the template strand. The arrows representing the PPRH are shown 
in the 5’ > 3’ orientation. TSS, transcription start site. 



































SEARCHING FOR POLYPURINE SEQUENCES USING THE TRIPLEX TARGET 
SITE MAPPING AND INTEGRATION SOFTWARE  
This alternate protocol uses different software which is located in a different web 
location. The present description illustrates an alternate option to search of 
polypurine stretches. The main difference is that the present one gives only 
sequences with up to one pyrimidine interruption. Additionally, it can filter the 
maximum number of Gs in a row. Given that 3 interruptions are allowed for the 
binding among PPRHs and their target, the BP1 is preferentially used. 
18. Connect via web with http://ttsmi.bii.a-star.edu.sg 
19. Introduce the name of the gene using the gene symbol, synonym or 
RefSeq ID. 
20. Establish the search criteria, which by default are: Percent guanine 
content, more than 40%; number of pyrimidine interruptions, 0; number of 
Gs in a row, less than 4. These parameters can be changed as desired, 
depending of the results after the first iteration, e.g. if there are no results, 
change from “0” to “1” pyrimidine interruption. 
21. The filtering options can be accurately adjusted by selecting the 
percentage of Gs, the minimum length of the polypurine sequence, and the 
gene region annotation. 
22. Submit the search to obtain the list of polypurine sequences including 
the information of the interruptions, length of the sequence, the %of Gs, and 
the gene regions where they are found. 
23. Design the sequence of the PPRH: Place the Polypurine sequence and 
link it to its reverse sequence using a T5 loop for connecting both sequences.   
 
BASIC PROTOCOL 2  
SYNTHESIS OF 8-AMINO-2’-DEOXYADENOSINE PHOSPHORAMIDITE 
8-Amino-2’-deoxyadenosine stabilizes the parallel triplex by the gain in one 
Hoogsteen purine-pyrimidine H-bond and the ability of the amino group to be 
integrated into the "spine of hydration" located in the minor-Major groove of the 
triplex structure (Güimil-García, 1999). This protocol describes the preparation of 
the phosphoramidite of 8-amino-2’-deoxyadenosine (Güimil Garcia, 1999). The 
synthesis involves 2 basic steps: synthesis of 8-amino-2’-deoxyadenosine and 
synthesis of the N-protected phosphoramidite derivative (Figure 3). The preparation 
of 8-amino-2’-deoxyadenosine involves 3 reactions: 1) bromination of 2’-
deoxyadenosine (dA), 2) displacement of the bromine by an azide group and 3) 
hydrogenation of the azide (Holmes, 1965; Long, 1967). Alternatively, it is possible 
to avoid hydrogenation by a simple treatment of 8-azido-2’-deoxyadenosine with 
40% aqueous methylamine (Frieden, 2003). The synthesis of the N-protected 
phosphoramidite derivative involves more 3 reactions: 4) introduction of the 
 
 
dimethylformamidino (dmf) group at N6 and N8 positions, 5) introduction of the 
dimethoxytrityl (DMT) group at the 5’-hydroxyl function and 6) preparation of the 
3’-O-phosphoramidite derivative.  
 










Lithium azide (Kodak) 
N,N-Dimethylformamide (DMF) 
Pd (5%) on carbon (Aldrich) 
Celite™ (Fluka) 
Hydrogen (H2) 
40% methylamine aqueous solution 
Dimethylacetal-N,N-dimethylformamide 
Silica gel (230-400 mesh, Grade 60, Fluka) 
Anhydrous pyridine 
Dimethoxytrityl chloride 
Sodium bicarbonate (NaHCO3) 
Sodium chloride (NaCl) 






2-Cyanoethoxy-N,N-diisopropylamino chlorophosphine (Link Technologies) 
Hexanes 
 
100- and 250-mL round-bottom flasks 
Magnetic stir bars 
Magnetic stirrer /hotplate 
Dropping funnel 
Silicone bath 
Dry ice/ acetone bath 
Rubber septa 
Syringe needles 
Buchner funnels setup with vacuum source 
Desiccator 
Hydrogenation apparatus (if using the hydrogenation route) 
Separation funnel 
Equipment for column chromatography 
 
Synthesis of 8-Bromo-2’-deoxyadenosine (2). 
1. Prepare a buffered bromine solution as follows: 2 ml of bromine was mixed 
with 40 mL of a 1M sodium acetate solution in a 250-mL Erlenmeyer flask by 
magnetic stirring until complete dissolution.  
2. Weight out 2.51 g (10 mmol) of 2’-deoxyadenosine (dA, 1, Figure 3) into a 
250-mL round bottom flask and add 20 mL of a 1M sodium acetate solution 
with stirring. A suspension is formed. Add dropwise (over 30 min) the 
buffered bromine solution to the dA suspension using a dropping funnel.  
3. After the addition of the bromine solution, stir the mixture for 2 hours at 
room temperature.  
4. Stop the reaction by addition of around 10 mL of a 38% NaHSO3 aqueous 
solution until the brown color of the solution changes to a pale yellow color.  
5. Adjust the pH of the solution to pH 7 
6. Cool the solution at -20 ºC with a dry ice/acetone bath. 
7. Filter the solution to obtain a precipitate and dry in a desiccator. 
The product (2) is a white-yellowish solid and it was obtained in 84% yield 
(2.77 g, 8.4 mmol). TLC (10% methanol (MeOH) / dichloromethane (DCM) Rf 
0.42; (20% MeOH/ DCM) Rf 0.58. 1H-NMR (250 MHz, DMSO-d6)  (ppm) 2.2 
(m, 1H, H-2’), 3.2 (m, 1H, H-2’), 3.4 (m, 1H, H-5’), 3.6 (m, 1H, H-5’), 3.83 
(m, 1H, H-4’), 4.42 (m, 1H, H-3’), 5.25 (wide s, 2H, 3’-OH and 5’-OH), 6.26 
(t, 1H, H-1’), 7.52 (wide s, 2H, NH2), 8.8 (s, 1H, H-2). 13C-NMR (62 MHz, 
DMSO-d6)  (ppm) 37.0 (C-2’), 62.1 (C-5’), 71.2 (C-3’), 86.4 (C-4’), 88.3 (C-
 
 
1’), 119.7 (C-5), 126.6 (C-8), 149.9 (C-4), 152.4 (C-2), 155.1 (C-6).  Mass 
spectra (electrospray +) expected for C10H12BrN5O3 329.2 and 331.2 (2 
isotopes of Br), found 330.02, 332.02 (M+H).            
Synthesis of 8-azido-2’-deoxyadenosine (3). 
8. Weight out 2.7 g (8.2 mmol) of 8-bromo-2’-deoxyadenosine (2) into a 250-
mL round bottom flask and dissolve in 30 mL of N,N-dimethylformamide 
(DMF) with magnetic stirring. Add 1 g of lithium azide (20.4 mmol). Cap the 
flask with a septum. 
9. Place the solution in a silicone bath placed on a hot plate and maintain the 
solution at 70ºC for 20 hr with magnetic stirring. 
10. Cool the solution to room temperature and concentrate the solution to 
dryness under vacuum using a rotovap. 
11. Dissolve the product in the minimal amount of hot water (around 40 
mL) and cool the solution at 4 ºC. Collect the resulting solid. 
The product (3) was obtained in 77% yield (1.84 g, 6.3 mmol) as a white 
solid. TLC (10% EtOH / DCM) Rf 0.22; (20% EtOH/ DCM) Rf 0.60. 1H-NMR 
(250 MHz, DMSO-d6)  (ppm) 2.1 (m, 1H, H-2’), 3.0 (m, 1H, H-2’), 3.42 (m, 
1H, H-5’), 3.6 (m, 1H, H-5’), 3.82 (m, 1H, H-4’), 4.41 (m, 1H, H-3’), 5.2 (s, 
2H, 3’-OH and 5’-OH), 6.1 (t, 1H, H-1’), 7.25 (s, 2H, NH2), 8.05 (s, 1H, H-2). 
13C-NMR (62 MHz, DMSO-d6)  (ppm) 37.1 (C-2’), 62.1 (C-5’), 71.0 (C-3’), 
83.4 (C-4’), 88.1 (C-1’), 117.0 (C-5), 144.0 (C-8), 149.3 (C-4), 151.5 (C-2), 
154.4 (C-6).         
Synthesis of 8-amino-2’-deoxyadenosine (4) by hydrogenation 
12. Weight out 3.5 g (12.2 mmol) of 8-azido-2’-deoxyadenosine (3) into a 
250-mL round bottom flask and dissolve in 100 mL of a 1:1 mixture of 
EtOH/water with magnetic stirring. 
13. Transfer the solution in a hydrogenation apparatus and add 400 mg of 
Pd (5%) on carbon. 
14. Maintain the suspension at 3 atmospheres of hydrogen during 72 hr 
with stirring. 
15. Empty the hydrogen using vacuum and add a nitrogen atmosphere. 
16. Open the hydrogenation apparatus and filter the mixture on Celite™. 
Wash the catalyst with 1:1 EtOH/ water solution.  
17. Concentrate the resulting filtrates to dryness under vacuum using a 
rotovap. 
18. Dissolve the product in the minimal amount of hot ethanol (around 40 
mL) and cool the solution at 4 ºC. Collect the resulting solid by filtration. 
 
 
The product (4) was obtained in 92% yield (3 g, 11.3 mmol) as a white solid. 
TLC (20% EtOH / DCM) Rf 0; (50% EtOH/ DCM) Rf 0.45. 1H-NMR (250 MHz, 
DMSO-d6)  (ppm) 2.0 (m, 1H, H-2’), 2.7 (m, 1H, H-2’), 3.5 (m, 2H, H-5’), 
3.9 (m, 1H, H-4’), 4.4 (m, 1H, H-3’), 6.25 (dd, 1H, H-1’), 6.6 (s, 2H, NH2), 
7.9 (s, 1H, H-2). 13C-NMR (62 MHz, DMSO-d6)  (ppm) 37.8 (C-2’), 61.8 (C-
5’), 71.4 (C-3’), 83.3 (C-4’), 87.6 (C-1’), 117.1 (C-5), 148.5 (C-2), 149.0 (C-
8), 151.5 (C-4), 152.4 (C-6).         
Alternate synthesis of 8-amino-2’-deoxyadenosine (4) by treatment with a 
40% methylamine aqueous solution 
19. Weight out 5.1 g (17.4 mmol) of 8-azido-2’-deoxyadenosine (3) into a 
screw-cap tube and dissolve in 20 mL of 40% aqueous methylamine solution 
and 2 mL of dioxane. 
20. Heat the solution overnight to 55 ºC 
21. Cool the solution to room temperature and evaporated to dryness 
under vacuum using a rotovap. 
22. Use the oily residue in the following step without further purification.  
23. The product has the same spectroscopy properties than the product 
obtained above.   
Synthesis of 8-amino-N6,N8-bis(dimethylaminomethylidene)-2’-
deoxyadenosine (5). 
24. Dissolve the 8-amino-2’-deoxyadenosine obtained above (approx. 17.4 
mmol) in 250 mL of DMF and add 12.1 mL of N,N-dimethylformamide 
dimethylacetal.  
25. Stir the solution overnight at room temperature and then concentrate 
to dryness. 
26. Dissolve the residue in DCM (20 mL) and purify the resulting 
compound using a silica gel column eluted with a 0-20% gradient of MeOH in 
DCM taking 20-mL fractions. The desired compound elutes at around 10% 
MeOH in DCM. Small amounts of 8-amino-2’-deoxyadenosine (4) may be 
observed at 20% MeOH in DCM. Combine the fractions containing the desired 
compound and concentrate to dryness under vacuum. 
The product (5) was an oil and it was obtained in 88% yield (5.4 g, 15.3 
mmol). TLC (10% EtOH / DCM) Rf 0.29. 1H-NMR (250 MHz, DMSO-d6)  
(ppm) 2.05 (m, 1H), 3.05-3.2 (3s and m, 13H), 3.5-3.6 (m, 2H), 3.86 (m, 
1H), 4.46 (m, 1H), 5.25 (m, 2H), 5.55 (m, 1H), 6.57 (t, 1H), 8.17 (s, 1H), 
8.66 (s, 1H), 8.81 (s, 1H). 13C-NMR (62 MHz, DMSO-d6)  (ppm) 34.4, 34.5, 
37.1, 40.4 (under solvent peak), 62.6, 71.7, 82.9, 87.8, 124.7, 148.4, 
151.6, 155.6, 156.0, 157.1, 157.6. Elemental analysis, expected for 
C16H24N8O3. ½ H2O C 49.86, H 6.54, N 29.07; Found C 49.52, H 6.57, N 





27. Dissolve 1.0 g (2.8 mmol) of compound 5 in 50 mL of anhydrous 
pyridine in a 100-mL round-bottom flask. The solution is stirred under 
nitrogen atmosphere on a magnetic stirrer and the flask capped with a 
rubber septum.  
28. Add 1.08 g of 4,4’-dimethoxytrityl chloride (3.18 mmol) to the pyridine 
solution in several small portions.  
29. After the last addition, stir for additional 2 hr at room temperature.  
30. Stop the reaction by adding 1 ml of MeOH and concentrated the 
solution to dryness under vacuum using rotovap. 
31. Dissolve the residue in DCM (40 mL) and wash the organic solution 
with 5% NaHCO3 aqueous solution (40 mL) and a saturated NaCl solution (40 
mL) (brine) using a separation funnel.  
32. Dry the organic solution with anhydrous Na2SO4  (1 g) and 
concentrated to dryness 
33. Pack a silica gel column with 1% triethylamine in DCM. Dissolve the 
residue in DCM (10 mL) and purify the compound with a 0-4% gradient of 
MeOH in DCM collecting 10 mL fractions. The desired compound elutes at 
around 3-4% MeOH in DCM. Small amounts of DMT-containing products 
eluted at pure DCM. Combine the fractions containing the desired compound 
and concentrate to dryness under vacuum using rotovap.  
The product (6) was obtained as white foam in 81% yield (1.5 g, 2.28 
mmol). TLC (5% EtOH / DCM) Rf 0.6. 1H-NMR (250 MHz, Cl3CD)  (ppm) 2.2 
(m, 1H), 2.93, 3.02, 3.07, 3.16 (4s and m, 13H), 3.4 (m, 2H), 3.69 (s, 6H), 
4.18 (m, 1H), 4.85 (m, 1H), 6.6-6.8 (m, 5H), 7.1-7.5 (m, 9H), 8.14 (s, 1H), 
8.68 (s, 1H), 8.71 (s, 1H). 13C-NMR (62 MHz, Cl3CD)  (ppm) 34.6, 34.8, 
36.4, 40.6, 40.8, 55.0, 64.4, 73.2, 82.4, 85.3, 85.9, 112.8, 124.8, 126.4, 
127.4, 128.0, 129.9, 136.0, 144.8, 149.2, 152.1, 153.3, 156.7, 156.8, 
157.5, 158.1. Mass spectra (electrospray +) expected for C37H42N8O5 678.8, 




34. Dissolve 1.16 g of compound 6 (1.7 mmol) in 20 mL of anhydrous 
acetonitrile and 0.9 mL (5.1 mmol) of diisopropylethylamine in a 50-mL 
round-bottom flask. The solution is stirred under nitrogen atmosphere on a 
magnetic stirrer and the flask capped with a rubber septum.  
 
 
35. Place the round-bottom flask in an ice bath and add 0.57 mL (2.55 
mmol) of 2-cyanoethoxy-N,N-diisopropylamino chlorophosphine with a 
syringe. 
36. After the addition, stir the solution for 1 hr at room temperature. 
37. Concentrate the solution to dryness under vacuum using rotovap. 
38. Dissolve the residue in DCM (40 mL) and wash the organic solution 
with 5% NaHCO3 aqueous solution (40 mL) using a separation funnel. 
39. Dry the organic solution with anhydrous Na2SO4  (1 g) and 
concentrated to dryness 
40. Pack a silica gel column with 1% triethylamine in DCM/hexanes (9:1).  
Dissolve the residue in DCM (10 mL) and purify the compound eluting with 
DCM/hexanes (9:1) collecting 10 mL fractions. Combine the fractions 
containing the desired compound and concentrate to dryness under vacuum 
using rotovap.  
The product (7) was obtained as white foam in 93% yield (1.4 g, 1.59 
mmol). TLC (DCM /hexanes 9:1) Rf 0.6. 31P-NMR (101 MHz, Cl3CD)  (ppm) 
144.96. Elemental analysis, expected for C46H59N10O6P C 62.86, H 6.77, N 
15.93; Found C 62.58, H 6.8, N 15.64.  
 
BASIC PROTOCOL 3 
SYNTHESIS OF 8-AMINO-2’-DEOXYGUANOSINE PHOSPHORAMIDITE 
8-Amino-2’-deoxyguanosine has been shown to stabilize both parallel (Soliva, 
2000) and antiparallel (Aviñó 2003) triplexes. This protocol describes the synthesis 
of the phosphoramidite of 8-amino-2’-deoxyguanosine needed for the preparation 
of oligonucleotides carrying 8-amino-2’-deoxyguanosine (Rao, 1994; Güimil García, 
1998; Rieger, 1999, Soliva, 2000). As described above the synthesis involves 2 
basic steps: synthesis of 8-amino-2’-deoxyguanosine and synthesis of the N-
protected phosphoramidite derivative (Figure 4). The preparation of 8-amino-2’-
deoxyguanosine involves 3 reactions: 1) bromination of 2’-deoxyguanosine (dG), 2) 
displacement of the bromine by hydrazine and 3) reduction of hydrazine with Raney 
Nickel (Long, 1967). The synthesis of the N-protected phosphoramidite derivative 
involves more 3 reactions: 4) introduction of the dimethylformamidino (dmf) group 
at N2 and N8 positions, 5) introduction of the dimethoxytrityl (DMT) group at the 5’-
O-hydroxyl function and 6) preparation of the 3’-O-phosphoramidite derivative 









Hydrazine hydrate (NH2NH2•H2O) 
Methanol (MeOH) 
Ethanol (EtOH) 






Silica gel (230-400 mesh, Grade 60, Fluka) 
Anhydrous pyridine 
Dimethoxytrityl chloride 
Sodium bicarbonate (NaHCO3) 
Sodium chloride (NaCl) 




2-Cyanoethoxy-N,N-diisopropylamino chlorophosphine (Aldrich) 
 
100- and 250-mL round-bottom flasks 
Magnetic stir bars 







Buchner funnels setup with vacuum source 
Equipment for column chromatography 
 
Synthesis of 8-Bromo-2’-deoxyguanosine (9). 
1. Prepare a bromine solution as follows: 1.4 g of bromine was mixed with 
138.6 mL of water in a 500 mL-round-bottom flask by magnetic stirring until 
complete dissolution (15 min). 
2. Weight out 5 g (18.8 mmol) of 2’-deoxyguanosine (dG, 8, Figure 4) into a 
500-mL round bottom flask and add 30 mL of water with stirring. A 
suspension is formed. Add the bromine solution to the dG suspension in 
fractions of 15 mL each until the suspension becomes permanently yellow 
and a white precipitate is formed (around 30 min).  
3. Filter immediately the suspension and collect the precipitate formed during 
the addition of the bromine solution. The precipitate is washed with cold 
water (50 mL) and cold acetone (20 mL). The solid is dried in a desiccator. 
The product (9) is a white solid and it was obtained in 84% yield (5.46 g, 
15.7 mmol). HPLC (see basic protocol 4, reversed phase, 5-50%B gradient in 
20 min) single peak at 13.7 min. 1H-NMR (250 MHz, DMSO-d6)  (ppm) 2.09 
(m, 1H, H-2’), 3.15 (m, 1H, H-2’), 3.54 (m, 2H, H-5’), 3.78 (m, 1H, H-4’), 
4.38 (m, 1H, H-3’), 5.24 (m, 2H, 3’-OH and 5’-OH), 6.14 (t, 1H, H-1’), 6.49 
(s, 2H, NH2), 10.8 (s, 1H, NH). 13C-NMR (62 MHz, DMSO-d6)  (ppm) 36.5 
(C-2’), 62.1 (C-5’), 71.0 (C-3’), 85.1 (C-1’), 87.9 (C-4’), 117.5 (C-5), 120.6 
(C-8), 152.0 (C-4), 153.3 (C-2), 155.5 (C-6). Mass spectra (electrospray +) 
expected for C10H12BrN5O4 345.2 and 347.2 (2 isotopes of Br), found 346.01 
and 348.01 (M+H), 368.00 and 370.00 (M+ Na), 409.02 and 411.02 
(M+Na+K), 691.02, 693.02 and 695.01 (2M+H), 713.00, 715.00 and 717.00 
(2M+ Na). 
Synthesis of 2’-deoxy-8-hydrazinoguanosine (10). 
4. Weight out 3.8 g (10.9 mmol) of 8-bromo-2’-deoxyguanosine (9) into a 250-
mL round bottom flask. The solid is suspended in a mixture of 50 mL water 
and 100 mL of methanol with magnetic stirring. Add 21.2 mL of NH2-
NH2•H2O (438 mmol) and fit a reflux condenser. 
5. Reflux the reaction mixture for 24 hr (approx. 90 ºC), then allow to cool to 
room temperature. 
6. Concentrate the reaction mixture to dryness under vacuum to obtaining a 
white solid.  
7. The residual solid is dissolved with the minimum amount of boiling methanol 
(around 50 mL) and allow cooling to room temperature and then to 4ºC, 
obtaining a white solid.  
 
 
8. The precipitate is collected by filtration. The solid is washed with anhydrous 
ether (30 mL) and dried in a desiccator.  
The product (10) as white solid was obtained in 56% yield (1.82 g, 6.1 
mmol). HPLC (see basic protocol 4, reversed phase, 5-50%B gradient in 20 
min) single peak at 5.4 min. UV (water) max 258 with shoulder at 280 nm. 
1H-NMR (250 MHz, DMSO-d6)  (ppm) 2.11 (m, 2H, H-2’), 3.60 (m, 2H, H-
5’), 3.77 (m, 1H, H-4’), 4.35 (m, 1H, H-3’), 6.14 (t, 1H, H-1’), 6.41 (s, 2H, 
NH2), 6.61 (s, 2H, NH2 hydrazino), 7.47 (s, 1H, NH hydrazine), 7.91 (s, 1H, 
NH). 13C-NMR (62 MHz, DMSO-d6)  (ppm) 37.5 (C-2’), 61.2 (C-5’), 71.1 (C-
3’), 82.4 (C-4’), 87.1 (C-1’), 112.1 (C-5), 150.7 (C-8), 151.5 (C-4), 152.5 
(C-2), 155.9 (C-6). Mass spectra (electrospray +) expected for C10H15N7O5 
297, found 298 (M+H). 
Synthesis of 8-amino-2’-deoxyguanosine (11) 
9. Weight out 1.4 g (4.7 mmol) of 2’-deoxy-8-hydrazino-guanosine (10) into a 
500-mL round bottom flask and dissolve in a mixture of 60 mL of water and 
100 mL of MeOH. 
10. Add 10 g of Raney™-Nickel and fit a reflux condenser. 
11. Reflux the reaction mixture for 16 hr. 
12. Filter the hot solution through a column filled with Celite™ to remove 
the catalyst. Washed the column with 100-200 mL of a hot solution of MeOH/ 
water (1:1) collecting the filtrates. 
13. Combine the filtrates and concentrate the mixture to dryness under 
vacuum.  
14. The residual solid is dissolved with the minimum amount of boiling 
mixture of MeOH/water (1:1) (around 30 mL) and allow to cool to room 
temperature and then to 4ºC, obtaining a white solid.  
15. The precipitate is collected by filtration and dried in a desiccator. 
The product (11) as white solid was obtained in 81% yield (1.1 g, 3.8 
mmol). TLC (20% MeOH in DCM) Rf 0.1. HPLC (see basic protocol 4, 
reversed phase, 5-50%B gradient in 20 min) single peak at 5.8 min. UV 
(water) max 259, 290 nm. 1H-NMR (250 MHz, DMSO-d6)  (ppm) 1.9 (m, 2H, 
H-2’), 3.4 (m, 2H, H-5’), 3.62 (m, 1H, H-4’), 4.33 (m, 1H, H-3’), 5.27 (d, 1H, 
3’-OH), 5.44 (t, 1H, 5’-OH) 6.09 (t, 1H, H-1’), 6.16 (wide s, 2H, NH2), 6.23 
(wide s, 2H, NH2), 10.7 (wide s, 1H, NH). 13C-NMR (62 MHz, DMSO-d6)  
(ppm) not available lack of solubility. Mass spectra (electrospray +) expected 





16. Dissolve 1 g of 8-amino-2’-deoxyguanosine (11, 3.5 mmol) in 60 mL 
of DMF and add 2.3 mL of N,N-dimethylformamide dimethylacetal (17.5 
mmol).  
17. Stir the solution overnight at room temperature and then concentrate 
to dryness under vacuum. 
18. Dissolve the residue in 10% EtOH in DCM (20 mL) and purify the 
resulting compound using a silica gel column eluted with a 10-15% gradient 
of EtOH in DCM taking 10 mL fractions. Combine the fractions containing the 
desired compound and concentrate to dryness under vacuum.   
The product (12) was obtained as oil in 99% yield (1.4 g, 3.5 mmol). TLC 
(20% EtOH / DCM) Rf 0.41. 1H-NMR (250 MHz, DMSO-d6)  (ppm) 2.05 (m, 
1H), 3.05-3.2 (3s and m, 13H), 3.5-3.6 (m, 2H), 3.86 (m, 1H), 4.46 (m, 
1H), 5.25 (m, 2H), 5.55 (m, 1H), 6.57 (t, 1H), 8.17 (s, 1H), 8.66 (s, 1H), 
8.81 (s, 1H). 13C-NMR (62 MHz, DMSO-d6)  (ppm) 34.2, 34.3 (2 CH3 dmf 
group), 38.4 (C-2’), 40.3, 40.6 (CH3 dmf group) , 62.8 (C-5’), 72.3 (C-3’), 
83.7 (C-4’), 87.4 (C-1’), 117.1 (C-5), 149.2 (C-8), 153.6 (C-4), 155.1 (C-2), 
156.6 (CH, dmf), 157.2 (c-6), 157.4 (CH, dmf). Mass spectra (electrospray 
+) expected for C16H24N8O4 392.4, found 393.2 (M+H), 785.3 (2M+ H). 
Synthesis of 8-amino-N2,N8-bis(dimethylaminomethylidene)-2’-deoxy-5’-
(4,4’-dimethoxytrityl)-guanosine (13). 
19.Dissolve 1.4 g of compound 12 (3.56 mmol) in 50 mL of anhydrous pyridine 
in a 100-mL round-bottom flask. The solution is stirred under nitrogen 
atmosphere on a magnetic stirrer and the flask capped with a rubber septum.  
20.Add 1.44 g of 4,4’-dimethoxytrityl chloride (4.3 mmol) to the pyridine 
solution in several small portions.  
21.After the last addition, stir for additional 2 hr at room temperature.  
22.Stop the reaction by adding 1 ml of MeOH and concentrated the solution to 
dryness under vacuum. 
23.Dissolve the residue in DCM (40 mL) and wash the organic solution with 5% 
NaHCO3 aqueous solution (40 mL) and a saturated NaCl solution (40 mL) 
using a separation funnel.  
24.Dry the organic solution with anhydrous Na2SO4 (1 g) and concentrated to 
dryness under vacuum. 
25.Pack a silica gel column with 1% triethylamine in DCM.  Dissolve the residue 
in DCM (10 mL) and purify the compound with a 0-10% gradient of MeOH in 
DCM collecting 10 mL fractions. The desired compound elutes at around 5% 
MeOH in DCM. Small amounts of DMT-containing products eluted at pure 
DCM. Combine the fractions containing the desired compound and 
concentrate to dryness under vacuum.  
 
 
The product (13) was obtained as white foam in 54% yield (1.35 g, 1.94 
mmol). TLC (10% EtOH / DCM) Rf 0.24, (20% EtOH / DCM) Rf 0.64. 1H-NMR 
(250 MHz, Cl3CD)  (ppm) 2.1 (m, 2H, H-2’), 2.86 (s, 3H, CH3 dmf), 2.98 (s, 
6H, CH3 dmf), 3.06 (s, 3H, CH3 dmf), 3.2 (m, 2H, H-5’), 3.71 and 3.72 (2s, 
6H, methoxy DMT), 3.87 (m, 1H, H-4’), 4.50 (m, 1H, H-3’), 5.23 (m, 1H, 3’-
OH), 6.47 (t, 1H, H-1’), 6.7-7.3 (m, 13H, DMT), 8.29 (s, 1H, CH dmf), 8.38 
(s, 1H, CH dmf), 11.1 (s, 1H, NH). 13C-NMR (62  MHz, Cl3CD)  (ppm) 34.2 
and 34.5 (2 CH3 dmf), 37.3 (C-2’), 40.2 and 40.7 (2 CH3 dmf), 54.6 
(methoxy DMT), 64.8 (C-5’), 72.4 (C-3’), 81.7 (C-4’), 85.0 (C-1’), 85.6 (Cq, 
DMT), 112.6 (DMT), 116.9 (C-5), 126.3 (DMT), 127.3 (DMT), 127.7 (DMT), 
129.7 (DMT), 135.8 (DMT), 144.6 (DMT), 149.5 (C-8), 153.4 (C-4), 154.2 
(C-2), 156.1 (CH, dmf), 157.1 (CH dmf and C-6), 158.0 (DMT). Mass spectra 





1. Dissolve 1.27 g of compound 13 (1.8 mmol) in 20 mL of anhydrous 
acetonitrile and 1 mL (5.5 mmol) of diisopropylethylamine in a 50-mL round-
bottom flask. The solution is stirred under nitrogen atmosphere on a 
magnetic stirrer and the flask capped with a rubber septum.  
2. Place the round-bottom flask in an ice bath and add 0.6 mL (2.73 mmol) of 
2-cyanoethoxy-N,N-diisopropylamino chlorophosphine with a syringe. 
3. After the addition, stir the solution for 1 hr at room temperature. 
4. Concentrate the solution to dryness under vacuum. 
5. Dissolve the residue in DCM (40 mL) and wash the organic solution with 5% 
NaHCO3 aqueous solution (40 mL) using a separation funnel. 
6. Dry the organic solution with anhydrous Na2SO4 (1 g) and concentrated to 
dryness under vacuum. 
7. Pack a silica gel column with 1% triethylamine in DCM. Dissolve the residue 
in DCM (10 mL) and purify the compound eluting with 0-1% MeOH gradient 
in DCM taking 10 mL fractions. Combine the fractions containing the desired 
compound and concentrate to dryness under vacuum.  
The product (14) was obtained as white foam in 61% yield (1.0 g, 1.11 
mmol). TLC (5% MeOH/ DCM) Rf 0.17, (10% MeOH/ DCM) Rf 0.75.  1H-NMR 
(250 MHz, Cl3CD)  (ppm) 1.1-1.2 (several d, 12H), 2.2-2.4 (m, 2H, H-2’), 
2.6 (m, 2H, -CH2CN), 2.99 (several s, 6H, CH3 dmf), 3.06 (several s, 6H, CH3 
dmf), 3.1-3.3 (m, 2H, H-5’), 3.57 (m, 2H, OCH2), 3.73 (several s, 6H, 
methoxy DMT), 4.1-4.2 (m, 1H, H-4’), 4.9 and 5.0 (2 diastereoisomers, 2m, 
1H, H-3’), 6.60 and 6.77 (2 diastereoisomers, 2m, 1H, H-1’), 6.7-7.3 (m, 
13H, DMT), 8.31 and 8.34 (2 diastereoisomers, 2s, 1H, CH dmf), 8.56 and 
 
 
8.58 (2 diastereoisomers, 2s, 1H, CH dmf).  31P-NMR (101 MHz, Cl3CD)  
(ppm) 145.7 and 145.5 (two diastereoisomers). Mass spectra (electrospray 
+) expected for C46H59N10O7P 895.0, found 895.4 (M+H), 1790.9 (2M+ H). 
 
BASIC PROTOCOL 4 
SYNTHESIS, PURIFICATION AND CHARACTERIZATION OF POLYPURINE 
HAIRPINS  
This protocol describes the synthesis of polypurine hairpins on solid-supports 
(Figure 4). As described in Figure 1 PPRH have two moieties: the complementary 
strand and the reversed Hoogsteen strand that can be linked by a polynucleotide 
(such as tetrathymidine or pentathymidine) loop or an organic linker such as 
hexaethyleneglycol (HEG) or similar. The connection can be done by any of the 
ends (configurations A or B from Figure 1). In any case the starting nucleotide is 
the one that has the 3’-end free and the synthesis on solid-phase is performed by 
regular protocols (Figure 5).  Most of the times PPRHs do not contain 8-aminopurine 
modifications and they can be easily obtained from commercial sources. On the 
other hand, it has been described that 8-amino-2’-deoxyguanine stabilizes both 
parallel (Soliva 2000) and antiparallel (Aviñó 2003) triplexes but 8-amino-2’-
deoxyadenosine stabilizes only parallel triplexes (Güimil-García 1999, Aviñó, 2003). 
Recently it has been demonstrated that PPRHs that contains 8-aminoguanine 
residues in the Watson-Crick purine strand have a positive effect in the triplex 
affinity capture of double stranded DNA for detection of DNA methylation (Huertas 
2018).   This positive effect due to the antiparallel-triplex stabilization of 8-
aminoguanine may be useful in future applications of PPRHs and for this reason the 





Figure 5. Scheme of the steps needed for the assembly of PPRHs A and B (Figure 
1) and parallel clamps C and D (Figure 1). P1, P2,…Pn purine sequence; Y1, Y2,…Yn 





(14  or Berry Associates) (if needed) 
5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidites 
(Link Technologies): 
 N2-Isobutyryl-2’-deoxyguanosine (ibu-dG-CE phosphoramidite) 
 N6-Benzoyl-2’-deoxyadenosine (Bz-dA-CE phosphoramidite) 
 Thymidine (dT-CE-phosphoramidite) (if needed for the loop) 
(4,4’-Dimethoxytrityl)-hexaethyleneglycol-O-(2-cyanoethyl)-N,N-diisopropyl 
phosphoramidite (C18 spacer, Link Technologies) (if needed for the loop) 
DNA controlled-pore glass (CPG) supports (Link Technologies) 
 ibu-dG-CPG (Link Technologies) 
 Bz-dA-CPG (Link Technologies) 
 Thymidine (dT 3’-CE-phosphoramidite) 
Reagents for DNA synthesis (Applied Biosystems, see also unit 3.1 and other units 
of Chapter 3): 
 
 
 Acetic anhydride in THF/pyridine 
16% 1-Methylimidizole in THF 
0.02 M Iodine in THF/pyridine/water 
1H-Tetrazole in anhydrous acetonitrile 




Illustra™ NAP™-10 column 
1M Triethylammonium acetate (TEAA) pH 7.0 (stock solution, unit A.2A.13) 
 
DNA synthesizer (e.g., Applied Biosystems Model 3400) 
Argon source  
HPLC column Nucleosil 120 C18 (250x8mm) 
Heating block 
SpeedVac concentrator 
Hamilton gas-tight syringe 
3-mL glass vials 
 
Solid-phase Synthesis of PPRH 
1. Dissolve 100 mol of 14 (if needed) in 1 mL of anhydrous acetonitrile in a 
10-mL vial used in the synthesizer capped with a rubber septum using a gas-
tight syringe. Load the vial in the synthesized using the change bottle 
protocol.  
2. Load the rest of the phosphoramidites, the rest of the DNA synthesis 
reagents and a DNA synthesis column with 1 mol of DNA controlled-pore 
glass (CPG) support corresponding to the first nucleoside at the 3’-end of the 
DNA sequence onto the synthesis port of the synthesizer.  
3. Perform the automated solid-phase assembly of the oligonucleotides from 3’ 
to 5’ using either DMT-on or DMT-off protocols. 
4. Remove the column from the synthesizer and dry the column with a stream 
of argon or nitrogen.  
5. If the PPRH does not contain 8-aminoguanine, transfer the CPG support to a 
3-mL vial, add 1 mL of concentrated aqueous ammonia and incubate the vial 
at 55 ºC overnight. If the PPRH contains 8-aminoguanine residues, use 0.1M 
DTT (dithiothreitol) or 2-mercaptoethanol solution in concentrated aqueous 
ammonia (Rieger 1999) and incubate for 24 hrs at 55ºC.  
Purification of PPRH 
6. Purify the sample by reversed-phase high performance liquid 
chromatography (RP-HPLC, Unit 10.5) using Nucleosil 120 C18 column eluted 
at a flow rate of 3mL/min with a 20 min linear gradient from 0-50% B and 5 
min isocratic at 50% B. Solutions were as follows. Solvent A: 5% CH3CN 
 
 
(Merck) in 100 mM triethylammonium acetate (TEAA) pH 7.0 and solvent B: 
70% CH3CN in 100 mM TEAA pH 7.0. 
7. Pool the fractions containing the desired oligonucleotide, concentrate the 
solution using a SpeedVac concentrator, and desalt by passing through an 
Illustra™ NAP™-10 column. 
8. Analyze the molecular weight by mass spectrometry (MALDI-ToF) 
 
ALTERNATE PROTOCOL 2 
SYNTHESIS, PURIFICATION AND CHARACTERIZATION OF PARALLEL 
OLIGONUCLEOTIDE CLAMPS 
This protocol describes the synthesis of oligonucleotide parallel clamps on solid-
supports (Figure 4). As described in Figure 1 parallel clamps have two moieties: the 
purine complementary strand and the pyrimidine Hoogsteen strand that can be 
linked by a polynucleotide (such as tetrathymidine or pentathymidine) loop or an 
organic linker such as hexaethyleneglycol (HEG) or similar. The connection can be 
done by any of the ends giving rise to two configurations (configuration C with 5’-5’ 
links or D with 3’-3’ links, Figure 1).  Sometimes parallel clamps may contain 8-
aminoguanine and/ or 8-aminoadenine residues in the Watson-Crick purine strand 
for stabilization purposes.  The preparation of 5’-5’ hairpins (C configuration) is 
performed in three parts (Figure 5): First, the preparation of the purine part 
carrying the modified 8-aminopurines using standard phosphoramidites for the 
natural bases and the 8-aminopurine phosphoramidites. The phosphoramidites of 8-
aminoadenine or 8-aminoguanine are prepared as described above or obtained 
from commercial sources. After the assembly of the purine part, a 
hexaethyleneglycol linker or a tetra- or pentathymidine sequence is added using the 
appropriate phosphoramidite. Finally, the pyrimidine part is assembled using 
reversed C and T phosphoramidites (Figure 5). For the preparation of 3’-3’ hairpins 
(D configuration) a similar approach is used (Figure 5). In this case, the pyrimidine 
part is assembled on solid supports functionalized with reversed C or reversed T 
(linked to the support through the 5' end) and reversed phosphoramidites (Figure 
6). This is followed by the addition of the hexaethyleneglycol or the addition of the 
tetra- or pentathymidine sequence.  The purine part is the last part to be 
assembled using standard phosphoramidites for the natural bases and the 8-




Figure 6. Scheme of a 5’-O-reversed phosphoramidite and controlled-pore glass 




guanosine)-3’-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (14 or Berry Ass. 
/ Glen Research) (if needed) 
8-Amino-N6,N8-bis(dimethylaminomethylidene)-2’-deoxy-5’-(4,4’-dimethoxytrityl-
adenosine)-3’-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (7, or Berry Ass./ 
Glen Research) (if needed) 
5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidites 
(Link Technologies): 
 N2-Isobutyryl-2’deoxyguanosine (ibu-dG-CE phosphoramidite) 
 N6-Benzoyl-2’-deoxyadenosine (Bz-dA-CE phosphoramidite) 
 Thymidine (dT-CE phosphoramidite) (if needed for the loop) 
(4,4’-Dimethoxytrityl)-hexaethyleneglycol-O-(2-cyanoethyl)-N,N-diisopropyl 
phosphoramidite (C18 spacer, Link Technologies) (if needed for the loop) 
3’-O-(4,4’-Dimethoxytrityl)-5’-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidites 
(Link Technologies): 
 N4-Benzoyl-2’-deoxycytidine (Bz-dC-CE 5’- phosphoramidite) 
 Thymidine (dT 5’-CE-phosphoramidite) 
DNA controlled-pore glass (CPG) supports (Link Technologies) 
 ibu-dG-CPG (Link Technologies) 
 Bz-dA-CPG (Link Technologies) 
 5’-Bz-dC-CPG (Link Technologies) 
 5’-dT-CPG (Link Technologies) 
Reagents for DNA synthesis (Applied Biosystems, see also unit 3.1 and other units 
of Chapter 3): 
Acetic anhydride in THF/pyridine 
16% 1-Methylimidizole in THF 
0.02 M Iodine in THF/pyridine/water 
1H-Tetrazole in anhydrous acetonitrile 




Illustra™ NAP™-10 column 
1M Triethylammonium acetate (TEAA) pH 7.0 (stock solution, unit A.2A.13) 
 
DNA synthesizer (e.g., Applied Biosystems Model 3400) 
Argon source 
HPLC column Nucleosil 120 C18 (250x8mm) 
Heating block 
SpeedVac concentrator 
Hamilton gas-tight syringe 




Solid-phase Synthesis of 5’-5’ and 3’-3’ Parallel Clamps 
1. Dissolve 100 mol of 7 and/or 14 (if needed) in 1 mL of anhydrous 
acetonitrile in a 10-mL vial used in the synthesizer capped with a rubber 
septum using a gas-tight syringe. Load the vial in the synthesized using the 
change bottle protocol.  
2. Load the rest of the phosphoramidites, the rest of the DNA synthesis 
reagents and a DNA synthesis column with 1 mol of DNA controlled-pore 
glass (CPG) support corresponding to the first nucleoside at the 3’-end of the 
DNA sequence onto the synthesis port of the synthesizer.  
3. Perform the automated solid-phase assembly of the oligonucleotides from 3’ 
to 5’ using either DMT-on or DMT-off protocols. 
4. Remove the column from the synthesizer and dry the column with a stream 
of argon or nitrogen.  
5. If the PPRH does not contain 8-aminoguanine, transfer the CPG support to a 
3-mL vial, add 1 mL of concentrated aqueous ammonia and incubate the vial 
at 55 ºC overnight. If the PPRH contains 8-aminoguanine residues, use 0.1M 
DTT or mercaptoethanol solution in concentrated aqueous ammonia (Rieger 
1999) and incubate for 24 hrs at 55ºC.  
Purification of Parallel Clamps 
6. Purify the sample by reversed-phase high performance liquid 
chromatography (RP-HPLC, Unit 10.5) using Nucleosil 120 C18 column eluted 
at a flow rate of 3mL/min with a 20 min linear gradient from 0-50% B and 5 
min isocratic at 50% B. Solutions were as follows. Solvent A: 5% CH3CN 
(Merck) in 100 mM triethylammonium acetate (TEAA) pH 7.0 and solvent B: 
70% CH3CN in 100 mM TEAA pH 7.0. 
7. Pool the fractions containing the desired oligonucleotide, concentrate the 
solution using a SpeedVac concentrator, and desalt by passing through an 
Illustra™ NAP™-10 column. 
8. Analyze the molecular weight by mass spectrometry (MALDI-ToF) 
 
BASIC PROTOCOL 5,   
USE OF CLAMPS OR POLYPURINE HAIRPINS IN GENE SILENCING 
EXPERIMENTS 
This protocol describes the preparation of PPRHs for gene silencing purposes. The 
design of the different types of PPRHs is already described in section 1. Here, we 
detail the steps associated to the dissolution of the synthesized PPRH in an aqueous 
buffer and the formation of a complex with a cationic liposome to transfect the 
 
 
PPRHs into the cells to achieve the silencing of the selected gene. The PPRH DNA 
which is negatively charged interacts with the positive charges carried by the 
cationic liposome, here illustrated by DOTAP, and after a brief incubation the mix is 
added to the cells. An important factor is the ratio between the concentrations of 
PPRH DNA and that of the liposome, which for PPRHs is around 1/100 
(DNA:liposome). The intracellular delivery can be easily followed visually with 
Fluorescent PPRHs (F-PPRH), which are obtained commercially (e.g. Sigma/Merck) 
using either a fluorescence microscope or a flow cytometer at different times after 
the beginning of the incubation. Depending of the parameter that needs to be 
determined, different periods of times are chosen for stopping the incubation or 
taking samples. The quantification of the remaining mRNA or protein compared to 
the control cells are carried out by optimized techniques of RT-qPCR or Western blot 
analysis which has been described thoroughly elsewhere (Rodriguez, 2013).  
 
Materials 
Polypurine reverse Hoogsteen Hairpins (PPRHs) 
TE (Tris/EDTA) buffer, pH 8.0 (see appendices unit A.2A.13)  
DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulphate 
(1 mg/ml) (from Biontex ) (C43H83NO8S, MW: 774.21) 
Culture medium for eukaryotic cells e.g. DMEM, RPMI, F12 
Fetal Calf Serum  
Automatic pipettes to measure between 1µl and 1000µl 
Glass pipettes to measure from 1 ml to 10 ml 
Culture dishes of 100 mm diameter for cell maintenance 
Culture dishes of 35 mm diameter for cell incubation with the PPRHs 
 
Preparation of PPRHs for gene silencing purposes 
1. After designing the different PPRHs, either template- or coding-, against a 
determined gene, proceed to synthesize them as non-modified 
oligonucleotide which can be also obtained from an oligonucleotide synthesis 
service (e.g. Sigma/Merck) and can be ordered at a scale of 0.05 micromol 
using desalting as purification method. 8-aminoguanine modification could 
offer an extra binding capability although they are only commercially 
available by specialized companies (e.g. Bio-Synthesis, Inc. Lewisville, Texas, 
USA) or they have to be synthesized using BP3 and BP4. In general, the 
range of length of PPRHs lie between 20 and 30 nucleotides, aiming if at all 
possible, for a length of 25 nt that confers high specificity. 
2. Resuspend the powder containing each PPRH to a final concentration in the 
tube of 100 µM (stock solution) using sterilized TE (Tris-EDTA, 10/1mM, pH 
8.0) buffer as solvent.  
3. Prepare a working solution of 10µM of PPRH, by making a dilution 1/10 from 
the 100 µM stock solution. 
 
 
4. Calculate the number of µL of the working solution to attain a final 
concentration in the cell medium of 100 nM; e.g. 10 µL for 1 ml of incubation 
medium, or 20µL for 2 ml of incubation medium. 
5. Mix 10µl of 10µM PPRH with 7.75 µl of cationic liposome DOTAP and 
incubation medium without Fetal Calf Serum (FCS) up to 200 µl and incubate 
in an Eppendorf for 20 min at room temperature. 
6. Add the 200 µl mixture containing the PPRH/DOTAP to 800µl of fresh medium 
with 10% FCS recently added to the incubation dish including the desired 
number of cells (1,000, 3,000, 10,000, 30,000, or 60,000) depending on the 
parameter to be determined, in a 35 mm diameter plate. This procedure will 
deliver a final concentration of 100 nM of the oligonucleotide with 10 µM 
DOTAP (ratio 1/100 DNA: liposome) when incubating the cells in 1 ml of 
medium. Scale the volume as needed. A wide range of cells lines have been 
transfected with PPRHs, such as human SKBR3, MCF7 and MDA-MB-468 from 
Breast cancer, PC3 prostate cancer, MiaPaCa from pancreas, HT29 and 
HCT116 colon cancer, monocytes THP-1, HEK293 and 786-O from kidney, 
K562 and Jurkat hematopoietic cells, HepG2, and HeLa cells, HUVEC primary 
cells, and also CHO K1 from Hamster. 
7. Incubate the PPRHs with the cells for different periods of time, depending of 
the parameter to be determined, e.g. 24 h for cellular uptake; 24-48h for 
mRNA; 48-72h for protein; 3-5 days for cell viability. 
 
BASIC PROTOCOL 6 
GOLD SURFACE FUNCTIONALIZATION WITH OLIGONUCLEOTIDE CLAMPS 
FOR SURFACE PLASMON RESONANCE. 
Surface plasmon resonance (SPR) is one of the most commonly used biosensors for 
nucleic acid detection. They detect biological interaction by measuring the 
variations of the optical light and consist of an optical system for excitation, the 
plasmonic transducer that is a thin film of gold that incorporates the biomolecular 
recognition element on its surface and finally a fluidic system for sample 
confinement at the sensing surface and flow delivery system for sample injection 
and delivery. For SPR for measurements of biological interest refer to Unit 20.4, 
Current protocols in Molecular Biology and for overview of Biacore systems and 
their applications and to Unit 19.13, Current Protocols in Protein Science. This 
protocol describes the biofunctionalization of oligonucleotide clamps on gold 
surfaces of a SPR biosensor and their hybridization with the target sequence. The 
SPR biosensor employed (Carrascosa, 2012; Aviñó, 2016; Huertas, 2018) is an 
integrated platform based on the Kretschmann configuration with a real-time 
monitoring of the intensity of the reflected light at a fixed angle of incidence. The 
synthesis of the probes includes the clamp sequence followed by a poly-thymidine 
spacer and a thiol group on the 5’-end. The spacer moves the clamp away from the 
surface and facilitates the accessibility of the clamp to the target sequence. 
Immobilization of thiolated probes can be generated ex-situ or in-situ the sensor 
 
 
apparatus. For the optimization of the clamp coverage and surface properties a 
horizontal spacer of 6-mercaptohexanol (MCH) or thiolated oligoethyleneglycol are 
commonly used. After immobilization of the probe, the addition of the target 
capture produces an increase in the refractive index of signal that is directly related 
to its concentration in the analyzed sample. Subsequent experiments consisted in 
dehybridization of the target with a regeneration solution, liberating the biosensor 
surface for further analysis with the same sensor. 
Materials 
Sensor chips made of a glass surface (10 × 10 × 0.3 mm) coated with 2 nm of 
chromium and 45 nm of gold (SSens, Enschede –The Netherlands)  




Buffer solutions were prepared by using milliQ water incubated overnight with 2% 
diethylpyrocarbonate (DEPC) and autoclaved at 121ºC for 1 hour  
5x Sodium chloride citrate (5XSCC) buffer: 750 mM NaCl, 75mM sodium citrate, pH 
7 
Phosphate buffer saline (PBS) 50 mM: 50 mM phosphate buffer, 0.75 mM NaCl, pH 
7 
Thiolated methyl-PEG (SH-PEG-CH3, MW: 2000 g/mol) 
6-Mercapto-1-hexanol (MCH) 
Diethyl pyrocarbonate (DEPC) (Sigma-Aldrich) 
 
UV/O3 Generator (Bioforce Nanosciences, USA) 
SPR instrument (Huertas, 2016) 
 
Gold Surface cleaning 
1. Clean the gold surface by sonication cycles (1 min) with solvents of 
increasing polarity (i.e. acetone, ethanol and MilliQ H2O) previously heated 
up to their boiling point.  
2. Dry under nitrogen flux and place the sensing surface in an UV/O3 generator 
(Bioforce Nanosciences, USA) for 20 min. Rinse the sensor chip with ethanol 
and water and dry. 
Clamp immobilization on gold chips and target hybridization 
3. Incubate ex-situ 100 µl of thiolated DNA probe with thiolated methyl-PEG or 
MCH (1:1) at total concentrations of 1µM in 50 mM PBS buffer (pH 7) in a 
humid chamber overnight at room temperature. Rinse the gold sensing 
surface with water and dry the chip prior setting up in the SPR instrument. 
4. Inject the sample containing the target sequence dissolved in 5XSSC buffer 
to hybridize (1-100 µM) to hybridize with the immobilized clamp probe. 




6. After the measure the surface is regenerated by washing with 20% 
formamide in 5XSSC buffer.  Alternatively, a solution of 20 mM NaOH may be 
used to disrupt target-probe interaction. 
 
REAGENTS AND SOLUTIONS 
TEAA buffer (trietylammonium acetate), 1M, pH 7.0 (stock solution) see Appendices 
unit A.2A.13 
SSC (Sodium chloride/sodium citrate), 20x (stock solution) see Appendices unit 
A.2A.12 
PBS (phosphate buffered saline), see Appendices unit A.2A.8  




Polypurine-polypyrimidine sequences are able to form a non-canonical structure 
constituted by three strands (Triplex). The third strand can be either a 
polypyrimidine (Hoogsteen strand) or a polypurine (reversed Hoogsteen strand) 
sequence forming parallel or antiparallel triplexes (see Figure 7). In both cases 
specific hydrogen bonds between the Watson-Crick purine strand and the 
Hoogsteen or reversed-Hoogsteen strand are formed. The triplex structure 
anticipates the potential use of a triplex-forming oligonucleotide (TFO) to bind to 
double stranded genomic DNA for therapeutic (antigene strategy) or for diagnostic 
(triplex affinity capture) purposes (Duca, 2008). The design of novel oligonucleotide 
derivatives for antigene inhibition of gene expression resulted in the discovery of 
peptide nucleic acids (PNA) (Hyrup, 1996) that have a strong affinity to DNA to 
form duplex PNA-DNA molecules but also very stable PNA-DNA-PNA triplexes (for 
RNA binding see Unit 4.60). The strong stability of PNA-DNA-PNA triplexes lead to 
the discovery of bis-PNA clamps (Nielsen, 2010) constituted by the Watson-Crick 
polypyrimidine sequences linked to the polypyrimidine Hoogsteen strand (Figure 6). 
These PNA clamps bind the target polypurine sequences in both single-stranded 
mRNA and double-stranded genomic DNA by strand displacement (Nielsen, 2010). 
The same strategy was described for the binding of polypyrimidine sequences but in 
this case the purine Watson-Crick strand is linked with the Hoogsteen or reversed 
Hoogsteen strand to form the so-called parallel clamps (Kandimalla, 1996; Aviñó, 
2002) or polypurine reversed hairpin (PPRH) (Coma, 2005) (Figure 7). The binding 
properties of the parallel clamps depend on the pH being more stable at slightly 
acidic pH as Hoogsteen cytosines are protonated in the parallel triplex (Robles, 
2002). The triplex stabilization properties of 8-aminopurine derivatives modulate 
this pH dependence observing parallel triplex at neutral pH (Aviñó, 2002; Güimil-
 
 
García, 1998; Güimil-García, 1999; Soliva 2000). The stabilization of the triplex at 
neutral pH by a combined effect of the gain in one Hoogsteen purine-pyrimidine H-
bond and the ability of the amino group to be integrated into the "spine of 
hydration" located in the minor-Major groove of the triplex structure (Aviñó, 2002). 
Moreover 8-aminoguanine also stabilizes antiparallel triplex (Aviñó, 2003). In order 
to use the beneficial triplex stabilization properties of 8-aminopurine, capture 
probes were designed as parallel clamps to bind to single-stranded polypyrimidine 
sequences. Examples of the use of these clamps are the isolation of polypyrimidine 
RNA sequences of biological interest such as bacterial RNA (Carrascosa, 2012) and 
miRNA (Aviñó, 2016). The same polypyrimidine sequences can be targeted by 
antiparallel hairpins. In this case the hairpins are formed by two antiparallel purine 
strands in which the stability of triplex does not depend on pH. The PolyPurine 
Reverse Hoogsteen (PPRH) technology is used for targeting single and double 
stranded nucleic acid sequences as PPRHs induce strand displacement (Coma, 
2005). PPRHs work at nanomolar range, like siRNAs, and at a lower concentration 
than that needed for antisense ODNs or TFOs. However, the stability of PPRHs is 
higher than that of siRNAs, as evidenced by their longer half-life. In addition, PPRHs 
are target-specific and non-immunogenic (Villalobos, 2014). They represent a tool 
to validate genes in proliferation and cancer (Villalobos, 2015) and can be used to 
target genes related to resistance (de Almagro, 2009), as chemosensitizers (de 
Almagro, 2011), and in immunotherapy (Bener, 2016; Medina, 2018). Several 
examples of PPRHs for the inhibition of gene expression have been described 
(Rodríguez, 2013; Rodríguez, 2015; Solé, 2017; Ciudad, 2017; Felix, 2018) as well 
as for the capture of miRNA (Ribas, 2018) and double-stranded DNA for the 
analysis of DNA methylation status (Huertas, 2018). 
The present unit describes the design, synthesis and properties of the parallel 
clamps and PPRHs. In addition to the hairpin geometry described, other 
oligonucleotide configurations have been described (Figure 7). These include cyclic 
oligonucleotides (Grimau, 2005), wedged (Rodriguez, 2015) and tail-clamps (Nadal, 
2005; Nadal, 2006). In all these cases a higher affinity polypyridine target and an 
increase in specificity has been observed. The methodology described in this unit is 
based in the sequential addition of the appropriate phosphoramidites. In the case of 
the synthesis of parallel clamps the synthetic protocol needs to assemble one of the 
strands in the reversed (5’-3’) direction. The strategy for the synthesis of these 
clamps implies the preparation of the polypyrimidine Hoogsteen strand using 5’-O-
phosphoramidites. Alternatively, it has been described the use of asymmetric 
branching units. These are diol derivatives protected with fluorenyloxycarbonyl 
(Fmoc) and DMT groups. These derivatives allow the synthesis of one of the strands 
elongating the DMT-protected part, and the assembly of the second strand in the 
normal 3’-5’ direction avoiding the need of reversed 5’-phosphoramidites (Aviñó, 
2004). Another alternative method for the preparation of parallel clamps avoiding 
the use of 5’-phosphoramidite is the preparation of both polypurine and 
polypyrimidine strands in a separate support and link them using Cu(I)-catalyzed 




Figure 7. Triplex forming oligonucleotides (TFO), clamps, PPRH, tail-clamps, cyclic 
and wedged oligonucleotides. 
An important issue in the design of clamps and PPRHs is the presence of 
interruptions in the target polypyrimidine sequence. In parallel clamps it has been 
suggested the use of the complementary base in the Watson –Crick strand and the 
use of C in the Hoogsteen strand for G interruptions and the use of G in A 
interruptions (Aviñó, 2002). In PPRH it has been suggested to add an A in the 
Watson-Crick position and another A in the Hoogsteen position (de Almagro, 2009). 
However, in later studies it was demonstrated that maintaining the pyrimidine 
interruption within the PPRH sequence conferred higher binding affinity and 
silencing effectiveness to the hairpin (Rodríguez, 2015). In Figure 8 it is shown the 
sequence and the mirror repeat structure of a PPRH designed against a 
polypyrimidine track present in the promoter of the human survivin gene (BIRC5). 
This polypurine sequence contains 3 pyrimidine interruptions in each strand.  
 
Figure 8. Example of the sequence and the mirror repeat structure of a PPRH 
designed against a polypyrimidine track present in the promoter of the human 
 
 
survivin gene (BIRC5). This polypurine sequence contains 3 pyrimidine 
interruptions in each strand. 
PPRHs are usually G-rich sequences. A concern on G-rich sequences is the 
possibility to have competing G-quadruplex structures that may lower the efficacy 
of triplex formation. This subject was studied in detail by Solé et al. 2017 
demonstrating that PPRHs can form triplexes with their target sequences even 
under conditions where they fold into G-quadruplexes.    
Critical Parameters and Troubleshooting 
Careful attention to the details of synthetic procedures is advised. Familiarity with 
routine organic synthesis protocols and solid phase oligonucleotide synthesis is 
recommended as they involve the use of flammable solvents and toxic chemicals. 
Adherence to good laboratory safety practices is required. All reactions should be 
conducted in ventilated fume hoods. The use of personal protective equipment 
including gloves, safety goggles, and a laboratory coat is required. Special attention 
is needed for catalytic hydrogenation and Raney™-Nickel reduction reactions as 
well as the manipulation of azides, hydrazine and bromine. Anhydrous solvents are 
required in most organic reactions. It is recommended to use good quality and 
anhydrous solvents in Sure/Seal bottles and to acquire the reagents for 
oligonucleotide synthesis in specialized DNA synthesis distributors.  
When using the dmf-protected 8-aminoguanine phosphoramidite, it is important to 
add 0.1 M 2-mercaptoethanol or DTT in the concentrated ammonia solution used in 
the final deprotection and to extent the deprotection time to 24 hrs to achieve 
completed removal of the dmf group (Rieger, 1999). 
Understanding Results 
The protocols described in this unit provide details on the preparation of the 
modified and unmodified parallel clamps and PPRHs. The assembly of the 
oligonucleotides proceeds in a similar manner than the assembly of standard 
oligonucleotides of similar sizes (20-50 bases long). There is no need to change the 
protocols for the purification of the oligonucleotides as they behave as standard 
oligonucleotides. In this unit we described the purification by reverse-phase HPLC, 
but ion exchange chromatography and gel electrophoresis as well as simple 
desalting over Sephadex™ columns can also be used as alternative purification 
methods. Yields are similar to the one obtained for standard oligonucleotides 
(around 30-60%) after HPLC purification. Sometimes parallel clamps may be 
obtained is slightly lower yields as reversed phosphoramidites may have lower 
coupling yields. Characterization of oligonucleotides is done by analysis of the 
homogeneity (single peak in HPLC or single band on gel electrophoresis) and 
determination of the molecular mass by MALDI mass spectrometry.  The binding 
properties of the clamps and PPRHs can be measured by hybridization with the 
target polypyrimidine strand and performing denaturation studies followed by UV 
spectrophotometry or circular dichroism (CD). Examples of these measures can be 
found in the bibliography (Aviñó, 2002, see also Unit 7.12). Usually two transitions 
can be observed on triplexes formed by a single oligonucleotide bound to a double-
 
 
stranded DNA. The first transition is the dissociation of the triplex-forming strand 
and the second transition is the denaturation of the duplex to random coil. When 
the triplex-forming strand is linked to the purine Watson-Crick strand (parallel 
clamps and PPRHs) the denaturation profiles shown only a single transition that 
corresponds to the triplex denaturation to random coil (Aviñó, 2002; Coma, 2005). 
In order to demonstrate triplex formation a control clamp with scrambled 
Hoogsteen or reversed Hoogsteen strand can be made and confirm that the melting 
temperature of the control sequence is lower than the melting temperature of the 
triplex (Aviñó, 2002; Coma, 2005). In addition, the formation of the parallel triplex 
can be demonstrated by the appearance of a band at 210 nm in the CD spectra 
(Figure 9) and a change in the UV spectra at 295 nm (Nadal, 2006).    
 
Figure 9. CD spectra of A) a parallel clamp (B22G, 3’-AGAGGAGGAAG-5’-(EG)6-5’-
CTTCCTCCTCT-3’) and B) a control clamp (B22Acontrol, 3’-AGAGGAGGAAG-5’-
(EG)6-5’-TTTTTCCCCCC-3’ ) alone and bound to their target polypyrimidine 
sequence (S11WC, 3’-CTTCCTCCTCT-5’). Upon binding to their target, the parallel 
clamp generates a negative band around 210 nm) while the control sequence do 
not generate this band (Aviñó 2002). Buffer conditions 50 mM NaCl, 10 mM MgCl2, 
0.1 M sodium phosphate pH 6. Adapted with permission from Aviñó, 2012. 
Copyright 2012, Oxford University Press. 
 
Time Considerations 
With prior experience in basic organic techniques each 8-aminopurine 
phosphoramidite can be prepared in 1 month. Oligonucleotides can be prepared in 
one working day. HPLC purification will need one day more. Parallel clamps cannot 
be easily obtained from commercially sources and there is a need for reversed 5’-O-
phosphoramidites and 5’-linked supports. Unmodified PPRH are easier to prepare 
and can be obtained from any oligonucleotide synthesis service company. As the 8-
aminopurine phosphoramidites can be obtained from commercial sources (Berry 
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associates), PPRH carrying 8-aminoguanine can be obtained from specialized 
oligonucleotide synthesis services.       
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Triplex-Forming Oligonucleotide Target Sequence Search software: available at 
http://utw10685.utweb.utexas.edu/tfo// 
Triplex target site Mapping and Integration software: available at http://ttsmi.bii.a-
star.edu.sg) 
Reverse Complement software: available at 
https://www.bioinformatics.org/sms/rev_comp.html) 
BLASTn software: available at 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) 
 
